MediBic To Start Providing Private DNA Bank Services In Japan
This article was originally published in PharmAsia News
In May, MediBic, a Tokyo-based biotechnology company specializing in pharmacogenomics, will start providing private DNA bank services, a personalized medical treatment advisory service targeting individuals. MediBic has been providing genetic information and projections on drug efficacy and side effects to major pharmaceutical companies. The DNA private bank is a service that will identify an individual's predisposition and health risks based on personal DNA and provide customers with medical treatment advice on an ongoing basis. Analysis of personal DNA could identify health risks and project future health developments such as illness, allowing more effective prevention and management, the company says. Initially targeting affluent customers, MediBic eventually plans to popularize the service by lowering the cost. (Click here for more-Japanese language
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.